nach oben

Drugs

Erschienen in:

01.08.2006 | Leading Article

Oral Anticoagulants in Development

Focus on Thromboprophylaxis in Patients Undergoing Orthopaedic Surgery

verfasst von: Dr Bengt I. Eriksson, Daniel J. Quinlan

Erschienen in: Drugs | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of the coagulation pathway indirectly. Recent research efforts have focused on the identification of small molecule inhibitors of the coagulation enzymes as novel therapies for thrombotic disorders. There has been particular success in developing nonpeptidic, orally available, small molecules to directly inhibit the key proteases, factor IIa and factor Xa.

Of the new oral anticoagulants in development, the two agents in the most advanced stage are dabigatran etexilate (BIBR 1048) and rivaroxaban (BAY 59-7939), which inhibit factor IIa and factor Xa, respectively. Other agents in the early stages of development include several Xa inhibitors (LY-517717, YM150, DU-176b and apixaban [BMS-562247]), a factor IXa inhibitor (TTP889), and an orally active glycosaminoglycan enhancer (odiparcil [SB-424323]), which indirectly enhances thrombin inhibition via heparin cofactor II. Results have been reported from important, phase II dose-finding studies, and a number of registration-track phase III studies have been initiated, reflecting the drive towards potentially more effective, but primarily safer and more convenient therapies for the prevention and treatment of venous and arterial thrombosis. Indeed, two unmet needs for anticoagulation that can be easily identified are safety and ease of use. Safety relates primarily to the incidence of major bleeding and this remains the key concern of orthopaedic surgeons, over and above any efficacy advantage, and convenience of use, which centres on oral administration replacing the need for injections.

The clinical development of these new anticoagulants is following the well tested strategy of dose-ranging and registration studies in major orthopaedic surgery, prior to development in arterial indications. There are a number of subtle issues, including the timing of the first perioperative dose, duration of prophylactic treatment and definition/assessment of study endpoints that can influence study outcome and require careful consideration when evaluating study results with new agents and in the comparison with established agents, and which are considered in this review.

It is anticipated that over the next 3 years, at least one of these agents will be successfully licensed for the prevention of venous thromboembolism after major orthopaedic surgery, which will act as a springboard for the gradual replacement of current anticoagulants.

Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the Vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published erratum appears in Chest 2005; 127: 415–6]. Chest 2004; 126 (3 Suppl.): 204–33SCrossRef

Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–9PubMedCrossRef

Turpie AG, Eriksson BI, Bauer KA, et al. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Chest 2003; 124 (6 Suppl.): 371–78SCrossRef

Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695–702PubMedCrossRef

Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867–73PubMed

Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353: 1028–40PubMedCrossRef

Dal Pozzo A, Acquasaliente M, Geron MR, et al. New heparin complexes active by intestinal absorption: I-multiple ion pairs with basic organic compounds. Thromb Res 1989; 56: 119–24CrossRef

Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs 2004; 64: 577–95PubMedCrossRef

Mohapatra R, Tran M, Gore JM, et al. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era. Am Heart J 2005; 150: 19–26PubMedCrossRef

10.

AstraZeneca. AstraZeneca decides to withdraw Exanta, Press Release, 14th February 2006 [online]. Available from URL: http://www.astrazeneca.com/pressrelease/5217.aspx [Accessed 2006 Mar 29]

11.

Bates SM, Weitz JI. New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol 2005; 144: 1017–28PubMedCrossRef

12.

Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005; 3: 1843–53PubMedCrossRef

13.

Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic. Curr Top Med Chem 2005; 5: 1677–95PubMedCrossRef

14.

Hampton T. New oral anticoagulants show promise. JAMA 2006; 295: 743–4PubMedCrossRef

15.

Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 338–400SCrossRef

16.

Committee for Proprietary Medicinal Products. Points to consider on Clinical Investigation of medicinal products for prophylaxis of intra- and post-operative venous thromboembolic risk. London: The European Agency for the Evaluation of Medicinal Products, 2000 Jun 29. Guideline no. CPMP/EWP/707/98

17.

ClinicalTrials.gov. A service of the U.S. National Institutes of Health developed by the National Library of Medicine [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 July 7]

18.

Mungall D. BIBR-1048 Boehringer Ingelheim. Curr Opin Investig Drugs 2002; 3: 905–7PubMed

19.

Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45: 1757–66PubMedCrossRef

20.

Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2: 1573–80PubMedCrossRef

21.

Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555–63PubMedCrossRef

22.

Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103–11PubMedCrossRef

23.

ClinicalTrials.gov. RE-NOVATE: a randomised, double-blind study to investigate the efficacy and safety of two different dose regimens of dabigatran etexilate compared to subcutaneous enoxaparin 40mg once daily for 28–35 days, in prevention of venous thromboembolism after primary elective total hip replacement surgery [online]. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/NCT00168818. [Accessed 2005 Nov 20]

24.

ClinicalTrials.gov. RE-MODEL (thromboembolism prevention after knee surgery): two different dose regimens of orally administered dabigatran etexilate capsules [150 or 220mg once daily starting with a half dose (i.e.75 or 110 mg) on the day of surgery] compared to subcutaneous enoxaparin 40mg once daily for 6–10 days [online]. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/NCT00168805 [Accessed 2005 Nov 20]

25.

ClinicalTrials.gov. RE-MOBILIZE: a phase III study investigating the efficacy and safety of two different dose regimens of dabigatran etexilate compared to enoxaparin in prevention of venous thromboembolism in patients with primary elective total knee replacement [online]. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/NCT00152971 [Accessed 2005 Nov 20]

26.

ClinicalTrials.gov. A randomized, parallel-group, double-blind, placebo controlled study to investigage the efficacy and safety of BIBR 1048 in prevention of venous thromboembolism in patients with primary elective total knee replacement [online]. Availalbe from URL: http://www.clinicaltrials.gov/ct/show/NCT00246025?order=5 [Accessed 2006 Mar 29]

27.

ClinicalTrials.gov. ThromboEmbolism Prevention Efficacy and Saftey Trial (TEMPEST) [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00041509 [Accessed 2005 Nov 20]

28.

GlaxoSmithKline. GSK cardiovascular & metabolic portfolio, September 21 2004 [online]. Available from URL: http://gsk.com/financial/presentations/merril_lynch-21sep2004/MerrillLynch-21sep2004.pdf [Accessed 2006 Mar 29]

29.

ClinicalTrials.gov. Odiparcil for the prevention of venous thromboembolism [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00244725 [Accessed 2005 Nov 20]

30.

Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479–86PubMedCrossRef

31.

Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121–8PubMedCrossRef

32.

Eriksson BI, Borris L, Dahl OE, et al. Prevention of venous thromboembolism after total hip replacement with once-daily BAY 59-7939: an oral, direct Factor Xa inhibitor [abstract]. Blood 2005; 106: A280

33.

Agnelli G, Haas SK, Krueger KA, et al. A phase II study of the safety and efficacy of a novel oral FXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR [abstract]. Blood 2005; 106: 278A

34.

Eriksson BI, Turpie AGG, Lassen MR, et al. YM150, an oral direct Factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery: a dose escalation study [abstract]. Blood 2005; 106: A1865

35.

ClinicalTrials.gov. A phase IIa, multi-center, multi-national, open label, dose ranging study of the efficacy, safety, and tolerability of oral DU-176b administered once or twice daily in the treatment of adult patients undergoing total hip arthroplasty [online]. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/NCT00107900. [Accessed 2005 Nov 20]

36.

ClinicalTrials.gov. A phase II randomized, double-blinded (BMS-562247 and enoxaparin), active-controlled (enoxaparin and warfarin), parallel-arm, dose-response study of the oral factor Xa inhibitor BMS-562247 in subjects undergoing elective total knee replacement surgery [online]. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/NCT00097357 [Accessed 2005 Nov 20]

37.

GlaxoSmithKline. Product development pipeline: February 2006 [online]. Available from URL: http://gsk.com/investors/product_pipeline/docs/pipeline.pdf [Accessed 2006 Jul 17]

38.

ClinicalTrials.gov. Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial): a multi-center, placebo-controlled evaluation of the safety and efficacy of three weeks extended VTE prophylaxis with daily oral doses of TTP889 after one week of standard prophylactic treatment following hip fracture surgery [online]. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/NCT00119457 [Accessed 2005 Nov 20]

39.

Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N- ( (5S)-2-oxo-3- [4- (3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48: 5900–8PubMedCrossRef

40.

Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412–21PubMedCrossRef

41.

Bayer. Novel, oral factor Xa inhibitor (BAY 59-7939): positive results of Phase II once-daily study presented. Press Release, 13th December 2005 [online]. Available from URL: http://www.news.bayer.com/baynews/baynews.nsf/id/B18107FBED611715C12570D60023DD41?Open [Accessed 2006 Mar 29]

42.

Lassen MR, Davidson BL, Gallus A, et al., on behalf of the Razaxaban investigators. A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, Razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery [abstract]. Blood 2003; 102: 15A

43.

Upreti VV, Khurana M, Cox DS, et al. Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: validation and application in a clinical study. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 831: 156–62PubMedCrossRef

44.

Fukuda T, Matsumoto C, Honda Y, et al. Antithrombotic properties of DU-176b, a novel, potent and orally active direct factor Xa inhibitor in rat models of arterial and venous thrombosis: comparison with fondaparinux, an antithrombin dependent factor Xa inhibitor [abstract]. Blood 2004; 104: 513A

45.

Furugohri T, Honda Y, Matsumoto C, et al. Antithrombotic and hemorrhagic effects of DU-176b, a novel, potent and orally active direct factor Xa inhibitor: a wider safety margin compared to heparins and warfarin [abstract]. Blood 2004; 104: 512A

46.

Morishima Y, Furugohri T, Isobe K, et al. In vitro characteristics, anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct factor Xa inhibitor, DU-176b [abstract]. Blood 2004; 104: 515A

47.

Turpie AGG, Bauer KA, Borris L, et al. Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa Inhibitor: pooled results of two phase IIb clinical trials [abstract]. Blood 2005; 106: A277

48.

Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000; 160: 2199–207

49.

Strebel N, Prins M, Agnelli G, et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451–6PubMedCrossRef

50.

Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833–40PubMedCrossRef

51.

Turpie AGG, Bauer K, Eriksson B, et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003; 90: 364–6PubMed

52.

Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 288–96PubMed

53.

Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703–12PubMedCrossRef

54.

Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490–6PubMedCrossRef

55.

Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873–80PubMedCrossRef

56.

Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46: 549–58PubMedCrossRef

57.

Dahl O, Eriksson B, Agnelli G, et al. ASA and NSAIDs with melagatran/ximelagatran or enoxaparin do not increase bleeding in patients undergoing joint replacement surgery. The METHRO III study [abstract]. J Thromb Haemost 2005; 3 Suppl. 1: P1627

58.

Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358: 9–15PubMedCrossRef

59.

Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135: 858–69PubMed

60.

Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1337–42PubMedCrossRef

61.

White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525–31PubMedCrossRef

62.

AstraZeneca. EXANTA (ximelagatran) tablets NDA 21-686. FDA Advisory Committee Briefing Document. Cardiovascular and Renal Drugs Advisory Committee. 2004 Sep 10. Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_01_AstraZeneca-Backgrounder.pdf. [Accessed 2006 Mar 29]

63.

Committee for Proprietary Medicinal Products. Recommendation on the need for revision of the guideline on clinical investigation of medicinal products for prophylaxis of intraand postoperative venous thromboembolic risk. London: The European Agency for the Evaluation of Medicinal Products, 2005 Nov 17. Guideline no. CPMP/EWP/707/98

64.

Turpie AG, Bauer KA, Eriksson BI, et al. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 2004; 126: 501–8PubMedCrossRef

65.

Kalebo P, Ekman S, Lindbratt S, et al. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment. Thromb Haemost 1996; 76: 893–6PubMed

66.

Kalebo P, Eriksson BI, Zachrisson BE. Central assessment of bilateral phlebograms in a major multicentre thromboprophylactic trial: reasons for inadequate results. Acta Radiol 1999; 40: 29–32PubMed

67.

Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215–21PubMedCrossRef

68.

Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thrombo-embolism after elective major knee surgery. N Engl J Med 2001; 345: 1305–10PubMedCrossRef

69.

Schellong SM, Beyer J, Halbritter K, et al. VENUS: a study to validate centrally adjudicated venous ultrasound against venography after major orthopaedic surgery [abstract]. Blood 2005; 106: A281

70.

Wallentin LC, Ezekowitz M, Simmers TA, et al. on behalf of the PETRO Investigators. Safety and efficacy of a new oral direct thrombin inhibitor Dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin [abstract]. Eur Heat J 2005; 26 Suppl. 1: P2949

71.

ClinicalTrials.gov. Randomized evaluation of long term anticoagulant therapY (RE-LY): comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial [online]. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/NCT00262600 [Accessed 2005 Nov 20]

72.

ClinicalTrials.gov. Use of SB424323 with aspirin in non-valvular atrial fibrillation in patients at a low or intermediate risk for stroke [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00240643. [Accessed 2006 Mar 29]

73.

ClinicalTrials.gov. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis: The Botticelli DVT study [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00252005. [Accessed 2006 Mar 29]

74.

ClinicalTrials.gov. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00291330. [Accessed 2006 Mar 29]

Titel: Oral Anticoagulants in Development
Focus on Thromboprophylaxis in Patients Undergoing Orthopaedic Surgery
verfasst von: Dr Bengt I. Eriksson
Daniel J. Quinlan
Publikationsdatum: 01.08.2006
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 11/2006
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666110-00001

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2006

Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia

Beclometasone Dipropionate/Formoterol in an HFA-Propelled Pressurised Metered-Dose Inhaler

Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer

Adalimumab

Adalimumab in Psoriatic Arthritis

Adalimumab in Psoriatic Arthritis